Published in Hum Vaccin Immunother on May 26, 2014
Plant-made oral vaccines against human infectious diseases-Are we there yet? Plant Biotechnol J (2015) 0.96
Combination vaccines against diarrheal diseases. Hum Vaccin Immunother (2015) 0.80
Recent advances in the production of recombinant subunit vaccines in Pichia pastoris. Bioengineered (2016) 0.77
The World Health Report 2006: working together for health. Educ Health (Abingdon) (2006) 39.73
2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis (2011) 7.79
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 7.41
Cholera vaccines: WHO position paper. Wkly Epidemiol Rec (2010) 5.24
Phase and antigenic variation in bacteria. Clin Microbiol Rev (2004) 5.02
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Shigellosis. J Microbiol (2005) 3.76
Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med (2005) 3.68
Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet (1984) 3.55
Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol (2009) 3.51
Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol (1994) 3.50
Enteric infections, diarrhea, and their impact on function and development. J Clin Invest (2008) 3.23
Diarrheal disease during Operation Desert Shield. N Engl J Med (1991) 3.22
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev (2008) 2.86
Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. Nat Rev Microbiol (2009) 2.54
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol (1991) 2.34
More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis (2005) 2.32
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol (2007) 2.11
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis (1995) 2.10
Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol (1972) 2.08
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol (2002) 1.76
Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis (1988) 1.76
Accelerating next-generation vaccine development for global disease prevention. Science (2013) 1.73
Isolation and characterization of chromatin subunits. Methods Cell Biol (1978) 1.68
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 1.67
Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain. Virology (1993) 1.59
Antioxidant effect of zinc in humans. Free Radic Biol Med (2004) 1.56
Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis (1992) 1.53
Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet (1987) 1.47
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun (2000) 1.44
Cholera toxin - a foe & a friend. Indian J Med Res (2011) 1.31
Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine (2006) 1.31
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine (2012) 1.31
The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis (1991) 1.29
Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology (1993) 1.26
Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics (1978) 1.25
Field assessment of a novel household-based water filtration device: a randomised, placebo-controlled trial in the Democratic Republic of Congo. PLoS One (2010) 1.25
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine (2010) 1.24
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Mucosal vaccine design and delivery. Annu Rev Biomed Eng (2012) 1.22
The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med (2013) 1.21
Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun (2001) 1.20
Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin (2007) 1.20
New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. J Immunol (2007) 1.17
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun (2002) 1.15
Cholera vaccines. Clin Infect Dis (2000) 1.13
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun (2005) 1.12
Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 1.12
An outbreak of El Tor cholera in Kavre district, Nepal. Kathmandu Univ Med J (KUMJ) (2006) 1.12
Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci U S A (2010) 1.11
Shigellosis: the current status of vaccine development. Curr Opin Infect Dis (2008) 1.10
Report of the 1966-67 cholera vaccine trial in rural East Pakistan. Bull World Health Organ (1972) 1.08
Campylobacter polysaccharide capsules: virulence and vaccines. Front Cell Infect Microbiol (2012) 1.08
New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol (2011) 1.08
Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun (2004) 1.07
The virosome concept for influenza vaccines. Vaccine (2005) 1.07
Isolation and genomic characterization of SfI, a serotype-converting bacteriophage of Shigella flexneri. BMC Microbiol (2013) 1.05
Multi-locus variable number tandem repeat analysis of 7th pandemic Vibrio cholerae. BMC Microbiol (2012) 1.04
Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine (2005) 1.03
Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 1.02
A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (2013) 1.02
A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol (2003) 1.00
Growth of rotaviruses in continuous human and monkey cell lines that vary in their expression of integrins. J Gen Virol (2000) 1.00
Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines (2011) 1.00
Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol (2012) 0.99
Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr (2012) 0.96
Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses (1997) 0.95
Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice. Gut (2013) 0.95
Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. Virology (2010) 0.94
Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine (2005) 0.94
Simple sari cloth filtration of water is sustainable and continues to protect villagers from cholera in Matlab, Bangladesh. MBio (2010) 0.93
Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut (2007) 0.93
Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients. J Clin Microbiol (1993) 0.93
Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks. PLoS Negl Trop Dis (2013) 0.92
Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol (2011) 0.91
Infectious diarrhea: new pathogens and new challenges in developed and developing areas. Clin Infect Dis (2006) 0.91
Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals (2013) 0.89
Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. Clin Vaccine Immunol (2011) 0.89
Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev (2005) 0.89
Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun (2005) 0.88
Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun (2003) 0.88
Innate cellular responses to rotavirus infection. J Gen Virol (2013) 0.88
Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA. J Toxicol (2012) 0.86
Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine (2009) 0.85
Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review. Expert Opin Biol Ther (2013) 0.85
Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice. Iran J Immunol (2008) 0.85
[Physiopathology of Rotavirus diarrhea]. Arch Pediatr (2007) 0.84
Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection. Vaccine (2007) 0.84
Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. PLoS One (2012) 0.83
Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine (2012) 0.83
Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines (2012) 0.83
The value of and challenges for cholera vaccines in Africa. J Infect Dis (2013) 0.83
Cholera-like enterotoxins and Regulatory T cells. Toxins (Basel) (2010) 0.82
Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells. J Inorg Biochem (2013) 0.82
Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine (2011) 0.82